Trump threatens 100% tariff on US drug makers that don’t strike deals to lower prices
Donald Trump is threatening 100% tariffs on US drug manufacturers who don't agree to lower domestic drug prices. The tariffs, targeting branded drugs and their active ingredients, aim to align US prices with those in other high-income countries.

Briefing Summary
AI-generatedDonald Trump is threatening 100% tariffs on US drug manufacturers who don't agree to lower domestic drug prices. The tariffs, targeting branded drugs and their active ingredients, aim to align US prices with those in other high-income countries. Exemptions are available for generic, orphan, veterinary, and specialty drugs, as well as companies that strike pricing deals with the White House and onshore production. Larger companies have 120 days to negotiate deals to avoid or reduce the tariff, while smaller companies have 180 days. The move comes amid pressure to lower consumer prices and Trump's broader economic agenda to address the rising cost of living, which he blames on the Biden administration. Some industry groups are concerned the policy favors large drugmakers.
Article analysis
Model · rule-basedKey claims
5 extractedCompanies that plan to increase their domestic manufacturing will see a 20% tariff that will increase to 100% in four years.
The executive order risks creating an “unfair two-tiered system of exemptions” benefiting only big companies.
Generic drugs, which make up more than 90% of medicines sold in the US, will be exempted from tariffs for at least one year.
Trump threatens 100% tariffs on US drug makers that don’t strike deals to lower prices.
US patients by far pay the most for prescription medicines, often nearly triple what patients pay in other developed nations.